摘要
目的探讨右美托咪定与星状神经节阻滞在偏头痛患者中的临床应用价值。方法选取该院收治的偏头痛患者130例,随机将患者分为研究组和对照组,每组65例。研究组患者采用右美托咪定与星状神经节阻滞的联合治疗方案,对照组患者则采用星状神经节阻滞的治疗方案,并分别比较和分析两组患者的临床指标改善情况和临床治疗效果。结果与对照组患者相比,研究组患者的偏头痛发作频率明显降低,偏头痛持续时间明显缩短,VAS评分值明显降低,治疗次数明显减少,差别均具有显著性(均P<0.05);研究组患者临床痊愈的比率和总有效率为50.77%和96.92%,明显高于对照组患者,差别具有显著性(P<0.05);研究组偏头痛患者的不良反应总发生率略有降低,为33.85%,两组间比较差别不具有显著性(P>0.05)。讨论右美托咪定联合星状神经节阻滞对于偏头痛患者临床治疗效果的改善和安全性的提高均具有积极的促进作用。
[ Objective ] To explore the clinical application value of dexmedetomidine combined with stellate ganglion block for migrainetreatment. [Methods] 133 patients with migraine were divided into study group and control group randomly, with 65 cases in each group. The patients in study group were treated with combination therapy with dexmedetomidine and stellate ganglion block. The patients in control group were treated with stellate ganglion block. The clinical indicators improvement and clinical ,~ffect of the patients in two groups were compared and analyzed. [ Results ] Compared with control group, the patients in study group the frequency of migraine attacks was reduced significantly, the migraine headache duration was shorted significantly, the VAS score was lowered significantly, the treatment time was reduced significantly（All P 〈0.（15）. Compared with control group, the rates of clinical cure and to- tal efficiency in study group were improved significantly, up to 50.77% and 96.92%（P 〈0.05）. The overall incidence of adverse reactions in study group was reduced （33.85%）, there were not significant difference in two groups （P 〈 0.05）. [ Conclusions] Dexmedetomidine combined with stellate ganglion block has positive role in improving the clinical effect and enhancing clinical safety for patients with migraine.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2014年第22期99-102,共4页
China Journal of Modern Medicine
